ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris
In This Article:
LYON, France, May 23, 2024--(BUSINESS WIRE)--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 13th, 2024, at 10:30 am, in the Jones Day’s offices, Hotel de Talleyrand, 2 rue Saint Florentin, 75001 Paris.
The notice of this shareholders’ meeting serving as convening notice was published on Monday, May 6th, 2024, in the French Bulletin des Annonces Légales Obligatoires ("BALO"), and includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting.
All documentation concerning the meeting is available to shareholders in accordance with the conditions set out in the regulations in force, and is available on the Company's website:
https://www.adocia.com/investors/general-meeting/
Precisions regarding the AGM:
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight (Paris time), will be able to participate physically in the AGM. Shareholders holding bearer shares ("actions au porteur") will need to obtain a certificate of shareholding ("attestation de participation") from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person.
Each shareholder may submit a question in writing to the Board of Directors, this question being treated during the shareholders meeting. Questions should be sent by registered mail with return receipt to the following address: ADOCIA, 115 avenue Lacassagne - 69003 Lyon or electronic communication to the following address: [email protected]. The written question must imperatively be accompanied by a certificate of attendance in order to be treated and must be sent no later than the fourth business day preceding the date of the shareholders’ meeting.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone? technology for the development of new generation insulins and products combining different hormones; 2) AdOral?, an oral peptide delivery technology; 3) AdoShell?, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel?, a long-acting drug delivery platform.